Search
Selected Filters
Filter Results
Displaying 21–30 of 64 news results
-
Oct 20, 2021
Opus Genetics Announces Two Key Leadership Appointments
Dr. Ash Jayagopal named Chief Scientific Officer and Mr. Joe Schachle appointed Chief Operating Officer.
-
Oct 7, 2021
Covid Revealed What Science Can Do When Funding is Found
‘In some ways, the pandemic ought to make us all feel more upbeat about the long-term future of medical research.’
-
Sep 22, 2021
Initial programs will focus on treatments for rare pediatric blinding conditions. Company formed to advance the work of scientific cofounders Dr. Jean Bennett, Junwei Sun and Dr. Eric Pierce.
-
Aug 4, 2021
Pediatric Ophthalmologists Target Inherited Retinal Diseases
New opportunities continue to develop in an evolving landscape.
-
Jul 20, 2021
Statement from Ben Yerxa, PhD, about Paralympian Becca Meyers
The Foundation believes that all people with disabilities should receive the accommodations necessary for their inclusion in all facets of society, especially when an individual may be unfamiliar with the area.
-
Jul 12, 2021
BioBonds in New York Times: Ask Congress to Support Biomedical Research for Treatments and Cures
Karen Petrou invented a new funding model for curing blindness. Proposed legislation aims to apply it to medical research more generally.
-
May 21, 2021
New Bipartisan Legislation Introduced to Boost Clinical Research for Treatments and Cures
The bill would provide loans to therapy developers ready to launch clinical trials for a broad range of conditions including eye diseases.
-
May 18, 2021
Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness. Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atlas Venture, Mission BioCapital and Foundation Fighting Blindness.
-
Feb 4, 2021
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
-
Jan 29, 2021
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board